TOPLINE:

Patients who initiated the dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) antiretroviral regimen during acute HIV infection had greater increases in BMI, systolic blood pressure, and cholesterol levels than those who initiated efavirenz/tenofovir disoproxil fumarate/emtricitabine (EFV/TDF/FTC), over nearly 2 years of follow-up.

METHODOLOGY:

Researchers conducted a retrospective study to evaluate changes in blood pressure and various metabolic parameters among patients with acute HIV infection who initiated either EFV- or DTG-based antiretroviral therapy regimens.

They analyzed 304 patients (median age, 26 years; 98% men) from the RV254 acute HIV infection cohort, of whom 160 initiated EFV/TDF/FTC and 144 initiated DTG/ABC/3TC.

From treatment initiation through 96 weeks of fol

See Full Page